Immuron Ltd (IMRN) stock
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.87−0.00 (-0.52%)
Close on Nov 18, 2026Market cap $6.99MP/E –Yield –
Immuron revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was A$7.71M, up 5.9% from the year before. Over ten years it grew 22.7% a year on average. The highest annual figure on record is A$7.71M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$7.71M | +5.9% |
| FY2025 | Jun 30, 2025 | A$7.29M | +48.6% |
| FY2024 | Jun 30, 2024 | A$4.90M | +171.7% |
| FY2023 | Jun 30, 2023 | A$1.80M | +135.8% |
| FY2022 | Jun 30, 2022 | A$765.19K | +424.9% |
| FY2021 | Jun 30, 2021 | A$145.78K | -94.2% |
| FY2020 | Jun 30, 2020 | A$2.52M | +5.5% |
| FY2019 | Jun 30, 2019 | A$2.39M | +63.9% |
| FY2018 | Jun 30, 2018 | A$1.46M | +4.3% |
| FY2017 | Jun 30, 2017 | A$1.40M | +39.5% |
| FY2016 | Jun 30, 2016 | A$1.00M | – |
See a number that looks wrong?